If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIxico Regulatory News (IXI)

Share Price Information for Ixico (IXI)

Share Price is delayed by 15 minutes
Get Live Data
8.25    0.00 (0.00%)
Bid:
8.00
Ask:
8.50
Spread: 0.50 (6.25%)
Market Cap: £18.07m
IXI Live PriceLast checked at - London Stock Exchange

Intraday Ixico Share Chart

Director/PDMR Shareholding

23 Jan 2020 07:00

RNS Number : 6513A
IXICO plc
23 January 2020
 

 

23 January 2020

IXICO plc

("IXICO" or the "Company")

 

Director and PDMR share purchase

IXICO plc (AIM: IXI), the AI data analytics company delivering insights in neuroscience, announces that it received notification on 22 January 2020 that on 21 January 2020 Giulio Cerroni, CEO of the Company, acquired 24,800 ordinary shares at an aggregated price of £0.802.

 

Giulio Cerroni is interested in 109,600 Ordinary Shares, representing 0.23 per cent of the issued share capital of the Company following the purchase.

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

 

Giulio Cerroni

 

2

 

Reason for the notification

 

a)

 

Position/status

 

 

CEO (PDMR)

b)

 

Initial notification /Amendment

 

 

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

 

IXICO plc

b)

 

LEI

 

 

 

2138005M1F59O6HWSA97

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

 

Description of the financial instrument, type of instrument

Ordinary Shares in IXICO plc

Identification code

GB00BCLY7L40

 

b)

 

Nature of the transaction

Acquisition

c)

 

Price(s) and volume(s)

 

 

 

 

 

Price(s)

Volume(s)

 

 

21/01/2020

 

 

 

£0.802

24,800

 

 

 

 

 

d)

 

Aggregated information

- Aggregated volume

24,800 shares

- Price

£0.802

e)

 

Date of the transaction

21/01/2020

f)

 

Place of the transaction

London Stock Exchange, AIM Market (IXI), UK

 

For further information please contact:

IXICO plc

Giulio Cerroni, Chief Executive Officer

 

+44 (0) 20 3763 7499

Grant Nash, Chief Financial Officer

 

Cenkos Securities PLC (Nominated adviser and sole broker)

Giles Balleny / Max Gould (Corporate Finance)

Michael F Johnson / Russell Kerr (Sales)

+44 (0) 20 7397 8900

Optimum Strategic Communications

Mary Clark, Supriya Mathur, Manel Mateus

IXICO@optimumcomms.com

+44 (0) 203 950 9144

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
DSHDLLFLBFLEBBF
Date   Source Headline
22nd Aug 20197:00 amRNSDirectorate Change
20th Aug 20195:38 pmRNSDirector/PDMR Shareholding
19th Aug 20194:40 pmRNSSecond Price Monitoring Extn
19th Aug 20194:35 pmRNSPrice Monitoring Extension
19th Aug 20197:00 amRNSTrading Update
9th Aug 20197:00 amRNSIXICO provides update on new & current contracts
23rd Jul 201911:05 amRNSSecond Price Monitoring Extn
23rd Jul 201911:00 amRNSPrice Monitoring Extension
11th Jul 20197:00 amRNSDirector and PDMR share purchase
10th Jun 20197:00 amRNSHolding(s) in Company
31st May 20197:00 amRNSHolding(s) in Company
31st May 20197:00 amRNSHolding(s) in Company
31st May 20197:00 amRNSHolding(s) in Company
31st May 20197:00 amRNSHolding(s) in Company
31st May 20197:00 amRNSHolding(s) in Company
22nd May 20197:00 amRNSHalf Yearly Report to 31 March 2019
10th May 20197:00 amRNSNotice of Results
25th Apr 20197:00 amRNSUpdate for first half of year ending 31 March 2019
24th Apr 20197:00 amRNSAnnounces two new biopharmaceutical contracts
12th Apr 20197:00 amRNSChange of Adviser
19th Mar 20194:20 pmRNSHolding(s) in Company
18th Mar 201912:24 pmRNSDirector/PDMR Shareholding
13th Mar 20197:00 amRNSDirector/PDMR Shareholding
5th Mar 20197:00 amRNSLate phase clinical study in Huntington's disease
1st Mar 20197:00 amRNSIXICO chosen for new Medical Imaging & AI Centre
7th Feb 20197:00 amRNSAppointment of Chief Financial Officer
11th Dec 20187:00 amRNSDirectorate Change
4th Dec 20187:00 amRNSFinal Results
4th Dec 20187:00 amRNSScope expanded with top 10 biopharma company
15th Oct 20187:00 amRNSPre-Close Trading Update
21st Sep 20184:46 pmRNSResult of General Meeting - Amended
21st Sep 201811:00 amRNSResult of General Meeting
11th Sep 20187:00 amRNSContract with top 10 global pharmaceutical company
3rd Sep 20187:00 amRNSProposed Capital Reorganisation
30th Aug 20187:00 amRNSContract expansion with biopharmaceutical company
21st Aug 20187:00 amRNSTrading Statement
13th Aug 20187:00 amRNSAgreement
13th Jun 20189:00 amRNSImplementation of Long Term Incentive Plan
12th Jun 20187:00 amRNSNotification of the cessation of a clinical trial
7th Jun 20189:47 amRNSIssue of Equity
31st May 20183:32 pmRNSHolding(s) in Company
31st May 20183:30 pmRNSHolding(s) in Company
30th May 201811:48 amRNSHolding(s) in Company
30th May 201811:45 amRNSHolding(s) in Company
30th May 20189:32 amRNSDirector/PDMR Shareholding
29th May 201812:08 pmRNSResult of General Meeting
23rd May 20183:29 pmRNSDirector/PDMR Shareholding
23rd May 20187:00 amRNSHalf-year Report
14th May 20187:00 amRNSNew contract with top 10 pharmaceutical company
10th May 20187:00 amRNSExpansion of two biopharmaceutical contracts

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.